0 results for 'Eli Lilly'
Autonomy CEO Downplays Panicked Emails, Denies Firm Was Tanking Before $11B Sale to HP
"What we're looking at is the sausage-making that goes into every quarter and the stress that goes into sales," Autonomy CEO Michael Lynch said of internal emails expressing alarm about the company's progress closing deals.DC Circuit Sides With Manufacturers in '340B' Drug Discount Dispute
"[W]e cannot plausibly interpret statutory silence to subject manufacturers to whatever delivery conditions any covered entity might find most convenient," Judge Gregory Katsas wrote for the appeals court.Big Law Seeks to Maintain M&A Momentum With Lateral Market Maneuvers
Firms such as Paul Weiss, Sullivan & Cromwell, Akin, K&L Gates and Seyfarth all announced lateral M&A partners in the last week.Surge in Social Media Drug Promotion Driving Calls for More Oversight
"I think the industry would like more clarity from the FDA on what exactly its position is on its authority over social media," said Mahnu Davar, a partner at Arnold & Porter Kaye Scholer.Judge Expands Ozempic Plaintiffs' Leadership Team, Names 4 Co-Lead Counsel
In a joint statement, the newly appointed leads said they "are honored to have been appointed by Judge Pratter to lead one of the most significant and consequential pharmaceutical injury cases of our time against the manufacturers of diabetes and weight loss drugs such as Ozempic and Wegovy."View more book results for the query "Eli Lilly"
As Eli Lilly's Insulin Pricing Settlement Unravels, Lawyers Vow to Push Ahead
Lawyers touting a $500 million settlement over insulin pricing are back at the drawing board after a judge refused to certify their class.Ozempic Plaintiffs Get Leadership Team, but Not Quite the One They Asked For
Walsh said that, during an extensive hearing on leadership structure last week, Pratter "had some concerns about the size of the committee that we put in the application."Civil RICO Suit Accuses Big Pharma and Benefit Managers of Insulin Price-Fixing
"Rather than working to lower insulin and other Type 2 diabetes medication prices, major [pharmacy benefit managers] and manufacturers use their dominant market positions to drastically increase the price of these necessary, life-saving medications, generating billions of dollars in illicit profits," co-lead counsel for the plaintiff claimed in a joint statement.Ozempic Leadership Fight Escalates: Proposed Co-Leads Are 'Losing Control'
Sarah Foster, of Schlesinger Law Offices in Fort Lauderdale, continued to insist she and others were excluded from the Ozempic leadership process, noting the last-minute addition of two lawyers to the proposed team.Insights and Strategies for Effective Succession Planning in AM Law 100 Firms
Brought to you by Gallagher
Download Now
State AI Legislation Is on the Move in 2024
Brought to you by LexisNexis®
Download Now
2024 ESI Risk Management & Litigation Readiness Report
Brought to you by Pagefreezer
Download Now
Creating a Culture of Compliance
Brought to you by Ironclad
Download Now